Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Saniona AB (publ)
  6. News
  7. Summary
    SANION   SE0005794617

SANIONA AB (PUBL)

(SANION)
  Report
Delayed Nasdaq Stockholm  -  11:19 2022-11-25 am EST
3.420 SEK   -0.15%
11/25Saniona AB's Nomination Committee for the Annual General Meeting 2023
GL
11/25Saniona AB's Nomination Committee for the Annual General Meeting 2023
AQ
11/21Saniona Q3 Update - Back to Scandinavian Levels
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Saniona extends runway and amends loan agreement with Formue Nord

10/03/2022 | 09:18am EST

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that Saniona and Formue Nord Fokus A/S (Formue Nord) have agreed to the change the terms of the loan agreement of June 30, 2021.

Saniona has repaid SEK 15 million of the loan and the maturity date for the outstanding loan value has been changed from June 30, 2023, to January 31, 2024. The current cash position is consequently expected to fund the planned activities until January 2024.

Thomas Feldthus, Chief Executive Officer of Saniona, commented, 'We continue to make progress on our partnering efforts, and I remain optimistic about being able to establish partnerships which will make us less dependent on the financial markets. The amended loan agreement will allow us to continue to pursue these efforts at the best possible terms without impacting share capital.'

In July 2021 Saniona entered into a non-dilutive term loan agreement for SEK 87 million with Formue Nord. Saniona has repaid SEK 15 million as of September 30, 2022. In connection with the repayment Saniona and Formue Nord have agreed to change the terms of the term loan agreement.

The term of the loan has been extended with 7 months, which means that the maturing date of the loan has been changed from June 30, 2023, to January 31, 2024. A 3% commitment fee will be paid to Formue Nord resulting in a loan value of SEK 74.2 million as of September 30, 2022. The loan value will continue to accrue at 1 per cent monthly interest until July 1, 2023, whereafter the monthly interest will increase to 1.5 per cent.

The changed terms of the loan means that the current cash position is expected to fund the planned activities until January 2024.

Contact:

Thomas Feldthus

Tel: +45 22109957

Email: thomas.feldthus@saniona.com

About Saniona

Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company's most advanced product candidate, Tesomet, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. These clinical trials are voluntarily paused due to funding limitations and Saniona is actively exploring partnering opportunities. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE, a database of more than 130,000 compounds, of which more than 20,000 are Saniona's proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly owned ion channel modulators, SAN711and SAN903. SAN711 has successfully completed a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions. SAN903 is in preclinical development for inflammatory and fibrotic disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about SANIONA AB (PUBL)
11/25Saniona AB's Nomination Committee for the Annual General Meeting 2023
GL
11/25Saniona AB's Nomination Committee for the Annual General Meeting 2023
AQ
11/21Saniona Q3 Update - Back to Scandinavian Levels
AQ
11/17Saniona publishes its interim report for the third quarter of 2022
GL
11/17Saniona AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
11/09Biostock : áSaniona ready for phase I with SAN903
AQ
11/03Saniona's anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical st..
GL
11/03Saniona AB Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for ..
CI
10/03Saniona extends runway and amends loan agreement with Formue Nord
AQ
09/30Saniona extends runway and amends loan agreement with Formue Nord
GL
More news
Financials
Sales 2022 13,0 M 1,25 M 1,25 M
Net income 2022 -181 M -17,4 M -17,4 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 213 M 20,5 M 20,5 M
Capi. / Sales 2022 16,4x
Capi. / Sales 2023 2,67x
Nbr of Employees 25
Free-Float 80,1%
Chart SANIONA AB (PUBL)
Duration : Period :
Saniona AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANIONA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,42 SEK
Average target price 6,50 SEK
Spread / Average Target 90,1%
Managers and Directors
Thomas Feldthus Chief Executive Officer
Anita Milland Site Manager-Denmark, VP-Finance & Administration
J°rgen Drejer Chairman & Deputy Chief Executive Officer
Palle Christophersen Senior Vice President-Research
Rudolf A. Baumgartner Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SANIONA AB (PUBL)-61.36%20
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930